We are live on ! Find out more
PR

PSP Research Portfolio holdings

AUM $188M Turnover 26.97%
This Fund
S&P 500
This Quarter Est. Return
+18.09%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$114M
AUM Growth
–
Cap. Flow
+$110M
Cap. Flow %
96.55%
Top 10 Hldgs %
65.84%
Holding
85
New
85
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 years
Top 10 Avg Time Held
0 years
Top 20 Avg Time Held
0 years

Top Buys

Rank Stock Value
1
SGOV icon
iShares 0-3 Month Treasury Bond ETF
SGOV
+$70.3M
2
LEGN icon
Legend Biotech
LEGN
+$699K
3
ACLX icon
Arcellx
ACLX
+$656K
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$601K
5
MLYS icon
Mineralys Therapeutics
MLYS
+$594K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Miscellaneous 61.41%
2 Healthcare 38.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
STOK icon
51
Stoke Therapeutics
STOK
$1.56B
$528K 0.46%
+16,621
New +$500K
2025 Q4
0 quarters
APGE icon
52
DELISTED
Apogee Therapeutics
APGE
$527K 0.46%
+6,984
New +$440K
2025 Q4
0 quarters
CRNX icon
53
DELISTED
Crinetics Pharmaceuticals
CRNX
$527K 0.46%
+11,316
New +$504K
2025 Q4
0 quarters
UTHR icon
54
United Therapeutics
UTHR
$22.9B
$526K 0.46%
+1,080
New +$503K
2025 Q4
0 quarters
MAZE icon
55
Maze Therapeutics
MAZE
$1.53B
$525K 0.46%
+12,672
New +$436K
2025 Q4
0 quarters
DNTH icon
56
Dianthus Therapeutics
DNTH
$4.03B
$524K 0.46%
+12,725
New +$493K
2025 Q4
0 quarters
DNLI icon
57
Denali Therapeutics
DNLI
$2.81B
$524K 0.46%
+31,762
New +$536K
2025 Q4
0 quarters
ALNY icon
58
Alnylam Pharmaceuticals
ALNY
$31B
$524K 0.46%
+1,318
New +$583K
2025 Q4
0 quarters
EXEL icon
59
Exelixis
EXEL
$15.4B
$524K 0.46%
+11,948
New +$494K
2025 Q4
0 quarters
XENE icon
60
Xenon Pharmaceuticals
XENE
$3.24B
$523K 0.46%
+11,678
New +$490K
2025 Q4
0 quarters
NAMS icon
61
NewAmsterdam Pharma
NAMS
$2.37B
$523K 0.46%
+14,920
New +$543K
2025 Q4
0 quarters
CELC icon
62
Celcuity
CELC
$2.77B
$523K 0.46%
+5,244
New +$431K
2025 Q4
0 quarters
KNSA icon
63
Kiniksa Pharmaceuticals
KNSA
$6.13B
$522K 0.46%
+12,655
New +$508K
2025 Q4
0 quarters
BMRN icon
64
BioMarin Pharmaceuticals
BMRN
$10.6B
$521K 0.46%
+8,772
New +$478K
2025 Q4
0 quarters
OCUL icon
65
Ocular Therapeutix
OCUL
$1.51B
$520K 0.45%
+42,853
New +$521K
2025 Q4
0 quarters
MDGL icon
66
Madrigal Pharmaceuticals
MDGL
$10.4B
$519K 0.45%
+892
New +$456K
2025 Q4
0 quarters
SNDX icon
67
Syndax Pharmaceuticals
SNDX
$1.15B
$519K 0.45%
+24,716
New +$431K
2025 Q4
0 quarters
SYRE icon
68
Spyre Therapeutics
SYRE
$7.47B
$519K 0.45%
+15,840
New +$414K
2025 Q4
0 quarters
VKTX icon
69
Viking Therapeutics
VKTX
$3.2B
$518K 0.45%
+14,714
New +$521K
2025 Q4
0 quarters
IMVT icon
70
Immunovant
IMVT
$5.52B
$516K 0.45%
+20,305
New +$453K
2025 Q4
0 quarters
BEAM icon
71
Beam Therapeutics
BEAM
$2.42B
$508K 0.44%
+18,334
New +$468K
2025 Q4
0 quarters
RYTM icon
72
Rhythm Pharmaceuticals
RYTM
$5.93B
$507K 0.44%
+4,738
New +$503K
2025 Q4
0 quarters
VERA icon
73
Vera Therapeutics
VERA
$2.01B
$506K 0.44%
+9,996
New +$355K
2025 Q4
0 quarters
INBX icon
74
Inhibrx
INBX
$1.32B
$505K 0.44%
+6,389
New +$435K
2025 Q4
0 quarters
CRSP icon
75
CRISPR Therapeutics
CRSP
$4.76B
$502K 0.44%
+9,580
New +$574K
2025 Q4
0 quarters
1 2
3
4

Similar funds

IJWM
Inman Jager Wealth Management Hattiesburg, Mississippi $188M AUM 19.49% 1-Year Est. Return
TCPG
Trivant Custom Portfolio Group San Diego, California $188M AUM 23.55% 1-Year Est. Return
KCPT
Kingstone Capital Partners Texas Frisco, Texas $188M AUM 26.67% 1-Year Est. Return
RMSCM
R.M. Sincerbeaux Capital Management New York $188M AUM 12.59% 1-Year Est. Return
AWP
Astra Wealth Partners Jersey City, New Jersey $188M AUM 26.79% 1-Year Est. Return
CFP
Comprehensive Financial Planning East Petersburg, Pennsylvania $188M AUM 48.26% 1-Year Est. Return
TCM
Thoma Capital Management Towson, Maryland $188M AUM 21.1% 1-Year Est. Return
TFP
Traction Financial Partners Encampment, Wyoming $188M AUM 20.42% 1-Year Est. Return

PSP Research's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for PSP Research, which disclosed 85 positions worth $114M. Its ten largest holdings account for 66% of the portfolio.

Its largest position is iShares 0-3 Month Treasury Bond ETF: 700,000 shares worth $70.3M.

By sector, the portfolio is most concentrated in Miscellaneous at 61% of assets, followed by Healthcare.

  • PSP Research's largest Q4 2025 buy was iShares 0-3 Month Treasury Bond ETF: 700,000 shares worth $70.3M.
  • PSP Research's ten largest holdings make up 66% of its $114M portfolio in Q4 2025.
  • PSP Research disclosed 85 positions in Q4 2025, its first 13F filing on record.

Based on PSP Research's 13F filing for Q4 2025, filed 6 Feb 2026.